NAS:ARCT (USA)
Arcturus Therapeutics Holdings Inc $ 55.14 0.84 (1.55%)
Volume:
675,699
Avg Vol (1m):
2,247,872
Market Cap $:
1.45 Bil
Enterprise Value $:
1.16 Bil
PE Ratio:
0.00
PB Ratio:
4.84
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 15.03 | ||
| Equity-to-Asset | 0.81 | ||
| Debt-to-Equity | 0.08 | ||
| Debt-to-EBITDA | -0.41 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 14.15 | ||
| Beneish M-Score | -2.39 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -499.16 | ||
| Net Margin % | -506.7 | ||
| ROE % | -59.98 | ||
| ROA % | -36.44 | ||
| ROC (Joel Greenblatt) % | -653.16 | ||
| 3-Year Revenue Growth Rate | -44.4 | ||
| 3-Year EBITDA Growth Rate | -63.2 | ||
| 3-Year EPS without NRI Growth Rate | -40.8 |
ARCT
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 4.84 | ||
| PS Ratio | 90.11 | ||
| EV-to-EBIT | -22.71 | ||
| EV-to-EBITDA | -23.08 | ||
| EV-to-Revenue | 113.21 | ||
| Current Ratio | 11.21 | ||
| Quick Ratio | 11.21 | ||
| Days Sales Outstanding | 86.98 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -56.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.83 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 14.14 | ||
| Earnings Yield (Greenblatt) % | -4.41 |